

## **Medicine summary -tranylcypromine (to date)**

			Case Group	Death Outcomes	Sole
Case Count			<b>125</b>	<b>1</b>	<b>63</b>
Reaction Count	Blood and lymphatic system disorders	Aplastic anaemia	<b>1</b>	<b>0</b>	<b>0</b>
		Pancytopenia	<b>1</b>	<b>0</b>	<b>0</b>
		<b>Blood and lymphatic system disorders</b>	<b>2</b>	<b>0</b>	<b>0</b>
	Cardiac disorders	Tachycardia	<b>4</b>	<b>0</b>	<b>1</b>
		Supraventricular tachycardia	<b>1</b>	<b>0</b>	<b>0</b>
		Palpitations	<b>5</b>	<b>0</b>	<b>2</b>
		<b>Cardiac disorders</b>	<b>10</b>	<b>0</b>	<b>3</b>
	Congenital, familial and genetic disorders	Congenital brain damage	<b>1</b>	<b>0</b>	<b>1</b>
		<b>Congenital, familial and genetic disorders</b>	<b>1</b>	<b>0</b>	<b>1</b>
	Ear and labyrinth disorders	Deafness	<b>2</b>	<b>0</b>	<b>2</b>
		Tinnitus	<b>2</b>	<b>0</b>	<b>2</b>
		Vertigo	<b>1</b>	<b>0</b>	<b>0</b>
		<b>Ear and labyrinth disorders</b>	<b>5</b>	<b>0</b>	<b>4</b>
	Endocrine disorders	Hyperprolactinaemia	<b>1</b>	<b>0</b>	<b>0</b>
		Inappropriate antidiuretic hormone secretion	<b>2</b>	<b>0</b>	<b>2</b>
		<b>Endocrine disorders</b>	<b>3</b>	<b>0</b>	<b>2</b>
	Eye disorders	Xerophthalmia	<b>1</b>	<b>0</b>	<b>1</b>
		Eye pain	<b>1</b>	<b>0</b>	<b>0</b>
		Mydriasis	<b>2</b>	<b>0</b>	<b>1</b>
		Photophobia	<b>1</b>	<b>0</b>	<b>0</b>
		Blindness transient	<b>1</b>	<b>0</b>	<b>1</b>
		Diplopia	<b>1</b>	<b>0</b>	<b>0</b>
		Visual impairment	<b>6</b>	<b>0</b>	<b>4</b>
		<b>Eye disorders</b>	<b>13</b>	<b>0</b>	<b>7</b>
	Gastrointestinal disorders	Tooth malformation	<b>1</b>	<b>0</b>	<b>1</b>
		Rectal haemorrhage	<b>1</b>	<b>0</b>	<b>1</b>
		Haematemesis	<b>1</b>	<b>0</b>	<b>1</b>
		Diarrhoea	<b>7</b>	<b>0</b>	<b>4</b>
		Constipation	<b>1</b>	<b>0</b>	<b>1</b>
		Dyspepsia	<b>1</b>	<b>0</b>	<b>0</b>
		Abdominal pain	<b>2</b>	<b>0</b>	<b>1</b>
		Dysphagia	<b>1</b>	<b>0</b>	<b>1</b>
		Nausea	<b>5</b>	<b>0</b>	<b>3</b>
		Vomiting	<b>7</b>	<b>0</b>	<b>2</b>
		Dry mouth	<b>1</b>	<b>0</b>	<b>0</b>
		Salivary hypersecretion	<b>1</b>	<b>0</b>	<b>0</b>
		<b>Gastrointestinal disorders</b>	<b>29</b>	<b>0</b>	<b>15</b>
	General disorders and administration site conditions	Hypothermia	<b>1</b>	<b>0</b>	<b>1</b>
		Hyperpyrexia	<b>1</b>	<b>0</b>	<b>0</b>
		Pyrexia	<b>7</b>	<b>0</b>	<b>2</b>
		Sudden death	<b>1</b>	<b>1</b>	<b>0</b>

## **Medicine summary -tranylcypromine (to date)**

Reaction Count		Case Group	Death Outcomes	Sole
	General disorders and administration site conditions	Asthenia	3	0 2
		Fatigue	3	0 3
		Malaise	3	0 0
		Influenza like illness	1	0 0
		Face oedema	1	0 0
		Chest pain	2	0 0
		Pain	1	0 1
		Chills	3	0 1
		Drug interaction	1	0 0
		Drug ineffective	2	0 2
		<b>General disorders and administration site conditions</b>	<b>30</b>	1 12
	Hepatobiliary disorders	Hepatitis cholestatic	1	0 1
		Jaundice	1	0 1
		Hepatic function abnormal	1	0 0
		Hepatic failure	1	0 0
		Hepatitis	1	0 0
		Hepatotoxicity	1	0 1
		<b>Hepatobiliary disorders</b>	<b>6</b>	0 3
	Infections and infestations	Abscess	1	0 1
		<b>Infections and infestations</b>	<b>1</b>	0 1
	Investigations	Blood creatine phosphokinase increased	1	0 1
		Red blood cell sedimentation rate increased	1	0 1
		Weight increased	3	0 1
		Globulins increased	1	0 1
		<b>Investigations</b>	<b>6</b>	0 4
	Metabolism and nutrition disorders	Decreased appetite	1	0 0
		Hyponatraemia	2	0 2
		Dehydration	1	0 0
		Hyperglycaemia	1	0 0
		Hypoglycaemia	2	0 0
		<b>Metabolism and nutrition disorders</b>	<b>7</b>	0 2
	Musculoskeletal and connective tissue disorders	Systemic lupus erythematosus	1	0 0
		Arthralgia	1	0 1
		Joint swelling	1	0 1
		Myalgia	3	0 2
		Muscle spasms	1	0 0
		Muscle twitching	1	0 0
		Muscle rigidity	1	0 0
		<b>Musculoskeletal and connective tissue disorders</b>	<b>9</b>	0 4
	Nervous system disorders	Cerebral haemorrhage	3	0 3

## **Medicine summary -tranylcypromine (to date)**

		Case Group	Death Outcomes	Sole
Reaction Count	Nervous system disorders	Subarachnoid haemorrhage	1	1 0
		Cerebrovascular disorder	1	0 1
		Headache	21	0 12
		Amnesia	2	0 1
		Dyskinesia	1	0 1
		Hypokinesia	1	0 1
		Paralysis	1	0 0
		Tremor	7	0 1
		Hyperreflexia	3	0 0
		Ataxia	2	0 2
		Nystagmus	1	0 0
		Coma	5	0 1
		Aphasia	1	0 0
		Somnolence	3	0 2
		Syncope	1	0 1
		Clonus	1	0 0
		Dizziness	8	0 2
		Meningism	1	0 0
		Paraesthesia	3	0 3
		Sensory disturbance	1	0 0
		Dysarthria	2	0 2
		Speech disorder	1	0 1
		Hypertonia	5	0 1
		Hypotonia	1	0 0
		Neuroleptic malignant syndrome	2	0 0
		Serotonin syndrome	9	0 1
		Grand mal convulsion	3	0 2
		Convulsion	6	0 0
		<b>Nervous system disorders</b>	<b>97</b>	<b>1 38</b>
	Pregnancy, puerperium and perinatal conditions	Intra-uterine death	1	0 0
		<b>Pregnancy, puerperium and perinatal conditions</b>	<b>1</b>	<b>0 0</b>
	Psychiatric disorders	Agitation	6	0 1
		Anxiety	4	0 2
		Nervousness	1	0 1
		Neurosis	1	0 1
		Bruxism	1	0 0
		Confusional state	13	0 3
		Disorientation	1	0 0
		Delirium	2	0 1
		Depression	1	0 0
		Delusion	1	0 0

## **Medicine summary -tranylcypromine (to date)**

Reaction Count			Case Group	Death Outcomes	Sole
Psychiatric disorders	Hallucination		2	0	0
	Hallucination, visual		1	0	0
	Thinking abnormal		1	0	1
	Euphoric mood		1	0	1
	Apathy		1	0	1
	Aggression		2	0	2
	Withdrawal syndrome		4	0	3
	Insomnia		6	0	4
	<b>Psychiatric disorders</b>		<b>49</b>	<b>0</b>	<b>21</b>
	Renal and urinary disorders		1	0	1
Reproductive system and breast disorders	<b>Renal and urinary disorders</b>		<b>1</b>	<b>0</b>	<b>1</b>
	Breast enlargement		1	0	0
	Erectile dysfunction		1	0	1
Respiratory, thoracic and mediastinal disorders	<b>Reproductive system and breast disorders</b>		<b>2</b>	<b>0</b>	<b>1</b>
	Dyspnoea		2	0	1
	Respiratory disorder		1	0	0
Skin and subcutaneous tissue disorders	<b>Respiratory, thoracic and mediastinal disorders</b>		<b>3</b>	<b>0</b>	<b>1</b>
	Urticaria		1	0	1
	Rash erythematous		2	0	0
	Photosensitivity reaction		1	0	1
	Pruritus		1	0	0
	Psoriasis		1	0	1
	Rash follicular		1	0	1
	Rash		1	0	0
	Rash generalised		1	0	1
	Rash maculo-papular		1	0	1
	Acne		1	0	1
	Hyperhidrosis		11	0	3
	Hirsutism		1	0	1
	Hypertrichosis		1	0	1
Vascular disorders	Purpura		2	0	1
	<b>Skin and subcutaneous tissue disorders</b>		<b>26</b>	<b>0</b>	<b>13</b>
Vascular disorders	Circulatory collapse		1	0	0
	Hypotension		6	0	2
	Orthostatic hypotension		4	0	2
	Flushing		1	0	1
	Hypertensive crisis		2	0	2
	Malignant hypertension		1	0	1
	Hypertension		16	0	5
	Vasculitis		1	0	1
	<b>Vascular disorders</b>		<b>32</b>	<b>0</b>	<b>14</b>

Cube updated:May 3, 2011 7:20:39 AM

## **Medicine summary -tranylcypromine (to date)**

Reaction Count	Reaction	Case Group	Death Outcomes	Sole
		333	2	<b>147</b>